1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Venture Life Group Plc

Venture Life Group Plc

LLSE:VLG
68.00
GBX
+1.00
(+1.49%)
6.98BMarket Cap
Feb 28Next Earn
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.01
0.02
0.27
0.26
0.39
0.44
0.34
0.24
0.35
0.26
0.35
0.18
0.21
- -
Basic EPS, GAAP
-0.03
-0.04
-0.06
-0.05
-0.04
-0.01
- -
0.01
0.03
0.02
- -
0.01
- -
- -
Free Cash Flow per Basic Share
-0.02
-0.05
-0.11
-0.05
-0.03
-0.01
-0.01
0.02
0.01
- -
0.04
0.06
0.07
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.02
0.45
0.4
0.39
0.38
0.39
0.39
0.57
0.58
0.6
0.6
0.59
0.59
Tangible Book Value per Share
-0.01
- -
0.08
0.04
-0.05
-0.05
0.14
0.14
0.36
0.06
-0.02
0.01
0.21
0.22
Basic Weighted Avg Shares
24
24
26
34
36
37
56
84
86
126
126
126
127
127
Sales/Revenue/Turnover
- -
- -
7
9
14
16
19
20
30
33
44
22
27
- -
Operating Margin (%)
-269.52
-204.32
-16.26
-15.95
-2
3.62
6.52
7.5
13.72
7.84
7.56
9.12
11.79
- -
Depreciation Expense
- -
- -
1
1
1
1
1
1
2
4
5
3
3
- -
Net Income, GAAP
-1
-1
-2
-2
-1
- -
- -
1
2
2
1
1
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
682.54
66.76
33.63
27.72
- -
26.35
- -
242.11
- -
Profit Margin (%)
-269.86
-222.43
-21.84
-19.4
-9.59
-2.29
1.26
4.47
7.87
7.33
1.18
4.12
-1.18
- -
Working Capital
- -
- -
6
4
4
4
14
14
49
16
18
2
53
54
LT Debt
- -
- -
3
3
6
10
5
5
9
12
23
4
22
22
Total Equity
- -
1
16
14
14
14
33
33
72
73
76
76
75
75
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-14.25
1.07
2.1
4.1
- -
1.71
- -
-4.41
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-14.38
1.07
2.38
4.23
- -
1.74
- -
-2.44
- -
Return on Common Equity (%)
- -
-316.08
-19.38
-11.96
-9.72
-2.57
1.01
2.75
4.51
3.31
0.7
1.21
-0.41
- -

Capital Structure

GBP

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
ST Debt
3
2
1
LT Borrowings
14
22
22
LT Finance Leases
4
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
127
127
128
Market Capitalization
57
50
70

Working Capital

GBP

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
Total Current Assets
29
72
74
Cash, Cash Equivalents & STI
6
3
2
Accounts Receivable, Net
13
10
10
Inventories
11
5
6
Total Current Liabilities
13
19
20
Payables & Accruals
- -
- -
- -
ST Debt
3
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.57%
24.6%
-1.11%
Free Cash Flow
157.8%
381.7%
1.91%
Net Income, GAAP
6.35%
5.61%
-134.09%
Sales/Revenue/Turnover
18.23%
12.35%
18.9%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
22
2024
- -
- -
27
2025
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jeremy Anthony Philip Randall
Full Time Employees
63
Sector
Health technology
Industry
Pharmaceuticals: major
Address
12 The Courtyard Bracknell BR United Kingdom RG12 2XB
IPO Date
Mar 28, 2014
Website
venture-life.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Venture Life Group plc Venture Life Group plc is a United Kingdom-based consumer self-care company that develops, manufactures and commercializes healthcare products including medical devices, food supplements, dermo-cosmetics and topical treatments primarily targeting the ageing population; its core portfolio encompasses oral care brands such as UltraDEX and Dentyl, women's intimate health products under Balance Activ and Health & Her/Him, glucose management solutions like Lift Glucose and Glucogel, ENT care offerings including Earol and EarolSwim, oncology support products such as Gelclair, Xonrid and Pomi-T, hemorrhoid treatments like Procto-eze Plus, and dermatology items including Mayo Clear and Rosa calma. Founded in 2010 and headquartered in Bracknell, Berkshire, the company operates across more than 90 global markets through over 200 partners, with key geographic focus in the United Kingdom, Netherlands, China, Germany, Italy, Switzerland, rest of Europe and internationally, serving consumers via pharmacies, retailers and B2B pharmaceutical channels in seven therapeutic areas spanning oral healthcare, women's health, neurology, dermatology and oncology support. In May 2025, Venture Life Group plc sold its contract development and manufacturing operations (CDMO) business, including facilities Biokosmes and Gnesta, to BioDue S.p.A. for €62 million in cash, enabling a strategic shift to a pure-play consumer healthcare platform focused on expanding its Power Brands; the transaction yielded a one-off profit of approximately £24.1 million, established a decade-long manufacturing agreement with the buyer to support ongoing production and innovation, particularly in food supplements, and provided resources for further investment in brand growth and accretive mergers and acquisitions in the consumer healthcare sector.